sefulness of monitoring sunitinib plasma concentration for the patients with metastatic renal cell carcinoma
Not Applicable
- Conditions
- metastatic renal cell carcinoma
- Registration Number
- JPRN-UMIN000043378
- Lead Sponsor
- agasaki University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Not provided
Exclusion Criteria
1 with liver and/or renal dysfunction (over ULNx2) 2 with severe heart failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sunitinib plasma concentration
- Secondary Outcome Measures
Name Time Method progression free survival periods, rate of adverse events